Ketanserin in the Treatment of Progressive Systemic Sclerosis
- 1 July 1988
- journal article
- research article
- Published by SAGE Publications in Angiology
- Vol. 39 (7) , 583-586
- https://doi.org/10.1177/000331978803900705
Abstract
Now progressive systemic sclerosis (PSS) is considered a disease of small vessels with which many immunologic alterations are associated. The presence in the blood of large amounts of serotonin can be considered a very important aggravating factor able to cause the sclerodermic alterations. The authors have treated 10 PSS patients with ketanserin, a selective antagonist of the S2 serotonin receptors, which are found in small vessels and platelets. Their results show that ketanserin represents an efficacious and very well tolerated therapy for treatment of the initial vascular symptoms of PSS.This publication has 11 references indexed in Scilit:
- Pathogenesis of Progressive Systemic SclerosisInternational Journal of Dermatology, 1986
- Treatment of raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5‐HT2) receptorArthritis & Rheumatism, 1984
- The Pharmacology of Specific, Pure and Potent Serotonin 5-HT2 or S2-AntagonistsPublished by Elsevier ,1982
- Increased Factor VIII/von Willebrand Factor Antigen and von Willebrand Factor Activity in Scleroderma and in Raynaud's PhenomenonAnnals of Internal Medicine, 1981
- The Microvascular Pathogenesis of Scleroderma: An HypothesisAnnals of Internal Medicine, 1979
- Endothelial injury in scleroderma.The Journal of Experimental Medicine, 1979
- Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamineBritish Journal of Dermatology, 1976
- Diffuse Systemic SclerodermaAnnals of Internal Medicine, 1962
- Raynaud's Disease, Raynaud's Phenomenon, and SerotoninAngiology, 1960